U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today that the U.S. Food and Drug Administration (FDA) has approved YESINTEK™ (Ustekinumab-kfce), a biosimilar to the reference product, Stelara® (Ustekinumab).

YESINTEK™, a monoclonal antibody, is approved for the treatment of Crohn's disease, Ulcerative Colitis, Plaque Psoriasis and Psoriatic Arthritis.

Biocon Biologics Ltd had previously notified the Stock Exchange on Feb 29, 2024, that the Company had entered into a settlement and licensing agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson (collectively known as Janssen) to commercialize YESINTEK™ in the United States of America no later than on February 22, 2025, upon approval from the U.S. FDA.

Shares of Biocon Limited was last trading in BSE at Rs. 364.80 as compared to the previous close of Rs. 363.80. The total number of shares traded during the day was 121583 in over 2141 trades.

The stock hit an intraday high of Rs. 368.15 and intraday low of 361.90. The net turnover during the day was Rs. 44412128.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 BioconBiologics USFDA YESINTEK Ustekinumabkfce Biosimilar Stelara